About this trial
This is a multi-cohort proof of concept study involving patients with sarcomas or melanomas. Patient models, both two- and three-dimensional, will be derived from tumour samples. These will then be used to evaluate drug sensitivities ex vivo.
Enrolled patients will undergo resections or biopsies as part of standard-of-care, which will be used to generate patient models. Patients will receive standard-of-care systemic treatment. Patient models will also be subjected up to a 14-drug screening panel. The majority of drugs in the respective drug panels has been shown to have activity in the respective cancers and would be used in the standard-of-care setting by treating physicians.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of sarcoma or melanoma
At least 1 tumour lesion amenable to fresh biopsy or resection
Signed informed consent from patient or legal representative
Able to comply with study-related procedures
Disqualifiers
There are no specific exclusion criteria if patients meet the inclusion criteria
Trial population
Patient aged between 21 to 99 diagnosed with sarcoma or melanoma.
Trial design
Case-only
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Percentage of patients with successful model generation for each tumour subtype.
Patients enrolled on study will undergo resection or biopsy of fresh tumour tissue to obtain cells for the generation of models.
Rates of radiological response from QPOP-directed treatment regimens.
Complete and partial clinical response and stable disease.
Survival outcomes from QPOP-directed treatment regimens.
Overall survival, progression-free survival.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.